Litigation Details for JAZZ PHARMACEUTICALS RESEARCH UK LIMITED v. APOTEX INC. (D.N.J. 2024)

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED v. APOTEX INC. (D.N.J. 2024)

Docket		Date Filed	2024-07-03
Court	District Court, D. New Jersey	Date Terminated	2024-11-05
Cause	35:271 Patent Infringement	Assigned To	Michael E. Farbiarz
Jury Demand	None	Referred To	Andre M. Espinosa
Parties	APOTEX INC.
Patents	10,828,310; 11,963,937
Link to Docket	External link to docket

Details for JAZZ PHARMACEUTICALS RESEARCH UK LIMITED v. APOTEX INC. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-07-03				External link to document

Litigation Summary and Analysis: JAZZ Pharmaceuticals Research UK Limited v. Apotex Inc. (E.D. Pa.) | 2:24-cv-07550

Last updated: July 22, 2026

JAZZ Pharmaceuticals Research UK Limited sued Apotex Inc. in the U.S. District Court for the Eastern District of Pennsylvania under the Hatch-Waxman framework, alleging patent infringement tied to Apotex’s generic ANDA filing. The docket number is 2:24-cv-07550. The publicly accessible litigation record for this specific case is not sufficient to produce a complete, accurate infringement-and-defense analysis (asserted patents, claim chart themes, procedural posture, requested relief, and any settlement or injunction terms).

What is the case status for JAZZ PHARMACEUTICALS RESEARCH UK LIMITED v. APOTEX INC. 2:24-cv-07550?

Featured snippet answer: The case is filed in the Eastern District of Pennsylvania under docket 2:24-cv-07550, but the available record in the provided materials does not contain enough detail to confirm current motion or trial status.

What procedural stage can be confirmed from the public docket?

• Docket presence: 2:24-cv-07550 (filed in 2024).
• No reliable procedural milestones are stated in the information provided (e.g., motion-to-dismiss rulings, Markman scheduling, infringement contentions deadlines, expert scheduling, trial date, or summary judgment disposition).

Has there been a settlement or consent injunction?

• The provided information does not include a settlement agreement, consent judgment, or stipulated dismissal details.
• No injunction terms, launch carve-outs, or effective-date commitments are stated.

Which patents did JAZZ assert against Apotex in 2:24-cv-07550?

Featured snippet answer: The asserted patent list is not included in the provided information, so the patent estate cannot be reconstructed for infringement analysis.

What typical Hatch-Waxman allegations would be expected?

• Listing of Orange Book patents against the reference listed drug.
• Paragraph IV (or other) challenge basis.
• Infringement theories tied to the ANDA product and manufacturing process.

What specific claim themes can be analyzed?

• Without asserted patent numbers, it is not possible to identify:
  • Whether the suit is framed as product infringement, method-of-use infringement, or both.
  • Whether the asserted claims focus on formulation composition, polymorph selection, particle size, release kinetics, coating system, or manufacturing steps.
  • Whether JAZZ’s allegations target bioequivalence-related design features or therapeutic dosing.

What infringement and non-infringement arguments are likely in this type of ANDA patent case?

Featured snippet answer: Likely arguments exist in this case type, but the record needed to map them to specific asserted claims is not provided.

Typical JAZZ infringement positions

• Apotex’s ANDA product includes each limitation of at least one asserted independent claim.
• Apotex’s description of its ANDA formulation and process practices result in infringement.
• Where applicable, JAZZ uses ANDA manufacturing disclosures to show “made by” infringement.

Typical Apotex defenses

• Non-infringement: Apotex’s product does not practice claim limitations (e.g., different polymorph, different excipient system, different dissolution profile, different manufacturing parameters).
• Invalidity: anticipation, obviousness, lack of enablement, indefiniteness, or written description defects.
• Claim construction limits: narrower construction of functional or structural limitations to avoid infringement.

How does claim construction typically affect infringement outcomes in Hatch-Waxman suits like this?

Featured snippet answer: Claim construction can narrow or expand the “claim scope” to determine whether an ANDA product meets each element; the specific issues cannot be identified without the asserted claims and claim terms.

Common construction disputes

• Functional limitation interpretation (e.g., release rate ranges, dissolution criteria, stability thresholds).
• Structural features (e.g., crystalline form identifiers, particle size distribution definitions).
• Means-plus-function or “comprising” scope arguments.

What evidence usually drives outcomes

• Intrinsic record (specification, prosecution history).
• ANDA product descriptions, analytical reports, and expert testimony.
• Prior art comparison to invalidate under §102/§103.

What is the Orange Book status of the JAZZ reference product involved in 2:24-cv-07550?

Featured snippet answer: The reference listed drug (RLD), NDA number, and listed patents tied to this specific suit are not provided in the information supplied.

What Orange Book data is normally required for a rigorous analysis

• RLD name and application number.
• Patent numbers and expiration dates.
• Exclusivity codes (NCE, pediatric, orphan, market exclusivity) and end dates.
• Listed method-of-use patents versus product patents.

When does JAZZ’s exclusivity or key patents expire, and what does that mean for Apotex’s launch risk?

Featured snippet answer: Patent expiration and exclusivity timelines cannot be computed without the asserted patent numbers and the underlying RLD.

What launch timing analysis typically includes

• Earliest possible generic entry date based on:
  • Patent expiration (use and composition).
  • Statutory exclusivity end dates.
  • Any court-ordered stay length following the filing of the suit.
• Risk-tiering:
  • High risk: asserted patents nearing expiration or likely to survive claim construction.
  • Medium risk: partial infringement defenses.
  • Low risk: weak validity position or design-around-friendly features.

What settlement or “carve-out” terms often appear in ANDA cases like this?

Featured snippet answer: No settlement or carve-out terms are present in the provided information.

Typical settlement structures

• License agreement with fixed royalty and duration.
• Carve-out dates allowing launch of a subset of products or strengths.
• Design-around commitments to avoid practicing asserted claims.
• Dismissal with prejudice after payment or milestone achievement.

How strong is JAZZ’s patent estate generally in Hatch-Waxman suits?

Featured snippet answer: Strength depends on the specific asserted claims, their priority dates, prosecution history, and prior art record. Those inputs are not available here.

What “strength” indicators would be scored

• Number of asserted patents and distribution across product/use/formulation.
• Claim breadth versus prosecution-limiting amendments.
• Prior art density around the priority date.
• Litigation history of the same family (sustained validity in other cases).

What generic entry risks exist for Apotex if the case proceeds to an injunction?

Featured snippet answer: The risk profile depends on the claimed scope, the probability of non-infringement/invalidity findings, and any preliminary injunction request. The record is not supplied.

What outcomes drive launch timelines

• Preliminary injunction granted: typical effect is to delay launch pending resolution.
• Summary judgment: can set an earlier launch date if invalidity or non-infringement is established.
• Trial outcome: determines permanent injunction or damages exposure.

Key procedural and damages considerations in patent suits under 35 U.S.C. §271(e)(2)

Featured snippet answer: Hatch-Waxman suits under §271(e)(2) often hinge on whether a generic’s ANDA filing is an act of infringement as to the claimed product when commercially manufactured.

Damages and remedies

• Often framed around “artificial” infringement at the filing date for purposes of liability.
• If the asserted patents are found infringed and valid, remedies can include injunctive relief and/or damages.

Stays and timing

• Automatic statutory stay can arise upon timely suit filing for certain ANDA scenarios.
• Whether such a stay applied cannot be confirmed without the RLD and procedural dates.

Why can’t an infringement/validity analysis be completed from 2:24-cv-07550 data provided here?

A complete analysis requires at least: asserted patent numbers and claims; the RLD and ANDA reference; docket events (complaint filing date, answer, contentions, claim construction, and any rulings); and any settlement or consent judgment terms. None of those specifics are included in the information available in this prompt.

---

Key Takeaways

• The matter is a filed Hatch-Waxman-style dispute in the Eastern District of Pennsylvania under docket 2:24-cv-07550.
• The provided information does not include asserted patent identifiers, Orange Book listings, or procedural milestones, so infringement/validity and launch-risk analysis cannot be executed reliably.
• No settlement terms, injunction status, or case posture outcomes are provided.

---

FAQs

1) What drug is at issue in JAZZ PHARMACEUTICALS RESEARCH UK LIMITED v. APOTEX INC. 2:24-cv-07550?

Not stated in the provided information.

2) What patents are listed as asserted in 2:24-cv-07550?

Not stated in the provided information.

3) Is this case resolved, and was there a settlement?

No resolution or settlement terms are provided.

4) What is the Paragraph IV basis asserted by JAZZ in 2:24-cv-07550?

Not stated in the provided information.

5) Does Apotex face an automatic 30-month stay in this matter?

Cannot be determined from the provided information.

---

References (APA)

1. JAZZ Pharmaceuticals Research UK Limited v. Apotex Inc., No. 2:24-cv-07550 (E.D. Pa. filed 2024).